Bluechiip Limited (Bluechiip or the Company) (ASX: BCT), a leader in the development of advanced sample management solutions for harsh environments, is pleased to announce a new partnership, including receipt of initial purchase orders, with the biospecimen repository of the NY State Psychiatry Institute (NYSPI).
NSPI, located in Columbia University in New York City, NY, manages and hosts a core biobanking facility for 12 clinics and academic research laboratories within Columbia University and the New York area. NYSPI has purchased Bluechiip Advanced Sample Management Solutions and placed initial orders for delivery of Bluechiip Enabled cryogenic labels for the management of both the existing sample inventory being moved into new facilities and the ongoing management of samples to be stored in the future.
Andrew McLellan, Bluechiip Managing Director, said, “We are delighted to be working with a leading facility in New York as we continue to grow our customer base and partnerships. Being partnered with a broad base of Ivy League research facilities further emphasizes Bluechiip’s applications. Their feedback will allow us to further expand our offerings for our core Bluechiip technology. World-renowned facilities of this nature, with substantial sample collections, act as an important reference point for Bluechiip as we grow our business especially in North America.”
The addition of NYSPI and its 12 associated clinical and academic research laboratories as partners and customers of Bluechiip, substantially grows Bluechip’s presence in the North American market. Bluechiip-enabled solutions are now in place in 25 laboratories across 12 customers.
Andrew McLellan added, “As our end-customer base grows to include world-renowned research organisations and large global pharmaceutical companies, as well as cell therapy, clinical trial and research organisations, we are seeing repeat ordering and forward order book growth. There are also significant opportunities to organically expand Bluechiip’s footprint and usage within each of these groups.”
The adoption by laboratories of Bluechiip-enabled solutions has grown steadily since launch, from four in the December 2021 quarter, to five in the March 2022 quarter, 10 in the June 2022 quarter, 12 in the September 2022 quarter, 13 in the December 2022 quarter, to 25 in the March 2023 quarter.
Authorised for release by the Bluechiip Limited Board